David Opperman, MD
Otolaryngology · Denver, CONPI 1144399197
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,001 of the $66,832 with a category attached, or 64.3%. Livanova USA, Inc. accounts for 90.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $23,936 and has fallen 94.8% since, to $1,234 in 2025. Among otolaryngology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $1909.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$61K
- Intuitive Surgical$6K
- Sanofi$23
- Johnson & Johnson$21
What the payments were for
- Consulting fees$17,09626%
- Speaking & faculty fees$43,00164%
- Travel & lodging$9281%
- Food & beverage$3070%
- Education$5,5008%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 23 | $60,614 |
| Intuitive Surgical | 10 | $6,174 |
| Sanofi | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THN Sleep Therapy$60,438
- DA VINCI SP$5,500
- Da Vinci Surgical System$583
How this compares
$66,832 in reported general payments places this provider in the 95th percentile of 174 otolaryngology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 23 | $388 |
| Famotidine | 17 | $319 |
| Azithromycin | 12 | $50 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Denver
- Owen ReichmanDenver$3K
- Christopher OliverDenver$3K
- Christopher LenkeitDenver$2K
- Elizabeth BoscoeDenver$2K
- Suzanne BertramFort Collins$475K
- Barton KnoxColorado Springs$164K
- Nicholas BeckmannColorado Springs$151K
- Vijay RamakrishnanAurora$128K
- Michael WilhelmColorado Springs$76K
- Andrew WinklerAurora$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.